[Stroke with leg paralysis -- cardioversion in atrial fibrillation: prevention of thromboembolism in risk patients].
D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000628:therapy*; D001780:Blood Coagulation Tests; D002648:Child; D002986:Clinical Trials as Topic; D004554:Electric Countershock; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010264:Paraplegia / Q000209:etiology*; D012307:Risk Factors; D020521:Stroke / Q000150:complications* / Q000209:etiology; D013923:Thromboembolism / Q000517:prevention & control*; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; C403769:certoparin